Nocebo and Psychological Factors in Irritable Bowel Syndrome (IBS): A Scoping Review
Downloads
Background: There is considerable information about the interrelation of functional gastrointestinal disorders (FGIDs) and psychological disorders, called gut-brain interaction. Physiological and psychological variables have been linked with the etiology and severity of IBS. The nocebo effect (the opposite of placebo) is defined as increase in pain or other symptoms after use of an inactive or inert treatment/agent purported to increase pain or unpleasant symptoms. Some psychological mechanisms of nocebo include expectancies, conditioning, learning, memory, motivation, somatic focus, reward, anxiety, and meaning. Moreover, neurobiological factors are associated with the etiology of this phenomenon. The aim of present study is a discussion of the definition, existence, prevalence, etiology, and characteristics of the nocebo effect in irritable bowel syndrome (IBS).
Methods: This paper presents a scoping review of the existence, frequency, and importance of the nocebo effect in IBS patients. Data sources included PubMed, PsycINFO, Google Scholar, and Scopus which were searched from their inception dates to 2022.
Results: The review of the obtained articles showed that psychological factors such as depression, anxiety, psychological distress, and some personality traits such as neuroticism are related to the occurrence of nocebo responses in IBS patients.
Conclusion: The psychological factors associated with nocebo responses include expectancies, conditioning, learning, memory, patient’s personality. Moreover, societal factors and the quality of the patient-physician interaction, and neurobiological factors influence the process of diagnosis, course, and treatment of IBS through nocebo responses. Compared to the extensive research data related to the placebo effect, there is little information and few articles on the role of nocebo, especially in FGIDs. This paper summarizes the scope and importance of the nocebo effect and IBS and its interrelations with psychological factors like personality, anxiety, depression, and psychological distress.
Downloads
Adibi, P., Keshteli, A. H., Esmaillzadeh, A., Afshar, H., Roohafza, H., & Bagherian-Sararoudi, R., et al. The study on the epidemiology of psychological, alimentary health and nutrition (SEPAHAN): Overview of methodology. J Res Med Sci 2012; 17(Spec 2): S291-S297
Amanzio, M., Howick, J., Bartoli, M., Cipriani, G. E., & Kong, J. (2020). How do nocebo phenomena provide a theoretical framework for the COVID-19 pandemic? Front Psychol, 11, 589884. doi:10.3389/fpsyg.2020.589884 [doi]. Retrieved from PM:33192929
Arksey, H., & O'Malley, L. (2005). Scoping studies: towards a methodological framework. Int J Soc Res Methodol, 8(1), 19-32.
Aslaksen, P. M., & Lyby, P. S. (2015). Fear of pain potentiates nocebo hyperalgesia. J Pain.Res, 8, 703-710. doi:10.2147/JPR.S91923 [doi];jpr-8-703 [pii]. Retrieved from PM:26491370
Beedie, C. J., Foad, A. J., & Coleman, D. A. (2008). Identification of placebo responsive participants in 40km laboratory cycling performance. J Sports Sci Med, 7(1), 166-175. Retrieved from PM:24150150
Beissner, F., Brunner, F., Fink, M., Meissner, K., Kaptchuk, T. J., & Napadow, V. (2015). Placebo-induced somatic sensations: a multi-modal study of three different placebo interventions. PLoS.One., 10 (4), e0124808. doi:10.1371/journal.pone.0124808 [doi];PONE-D-14-40891 [pii]. Retrieved from PM:25901350
Benedetti, F. (1996). The opposite effects of the opiate antagonist naloxone and the cholecystokinin antagonist proglumide on placebo analgesia. Pain., 64(3), 535-543. doi:00006396-199603000-00017 [pii];10.1016/0304-3959(95)00179-4 [doi]. Retrieved from PM:8783319
Benedetti, F., Amanzio, M., Vighetti, S., & Asteggiano, G. (2006). The biochemical and neuroendocrine bases of the hyperalgesic nocebo effect. J Neurosci, 26(46), 12014-12022. doi:26/46/12014 [pii];10.1523/JNEUROSCI.2947-06.2006 [doi]. Retrieved from PM:17108175
Benedetti, F., Lanotte, M., Lopiano, L., & Colloca, L. (2007). When words are painful: unraveling the mechanisms of the nocebo effect. Neuroscience, 147(2), 260-271. doi:S0306-4522(07)00181-9 [pii];10.1016/j.neuroscience.2007.02.020 [doi]. Retrieved from PM:17379417
Benedetti, F., & Shaibani, A. (2018). Nocebo effects: More investigation is needed. Expert.Opin.Drug Saf, 17(6), 541-543. doi:10.1080/14740338.2018.1474199 [doi]. Retrieved from PM:29768057
Blasini, M., Corsi, N., Klinger, R., & Colloca, L. (2017). Nocebo and pain: An overview of the psychoneurobiological mechanisms. Pain.Rep., 2(2). doi:10.1097/PR9.0000000000000585 [doi]. Retrieved from PM:28971165
Carco, C., Young, W., Gearry, R. B., Talley, N. J., McNabb, W. C., & Roy, N. C. (2020). Increasing evidence that irritable bowel syndrome and functional gastrointestinal disorders have a microbial pathogenesis. Front Cell Infect Microbiol, 10, 468. doi:10.3389/fcimb.2020.00468 [doi]. Retrieved from PM:33014892
Chavarria, V., Vian, J., Pereira, C., Data-Franco, J., Fernandes, B. S., Berk, M. et al. (2017). The Placebo and nocebo phenomena: Their clinical management and impact on treatment outcomes. Clin Ther, 39(3), 477-486. doi:S0149-2918(17)30077-2 [pii];10.1016/j.clinthera.2017.01.031 [doi]. Retrieved from PM:28237673
Chey, W. D. (2018). Diet and irritable bowel syndrome. Gastroenterol Hepatol.(N.Y.), 14(5), 309-312. Retrieved from PM:29991939
Colloca, L., & Benedetti, F. (2005). Placebos and painkillers: Is mind as real as matter? Nat.Rev.Neurosci, 6(7), 545-552. doi:nrn1705 [pii];10.1038/nrn1705 [doi]. Retrieved from PM:15995725
Corsi, N., & Colloca, L. (2017). Placebo and nocebo effects: The advantage of measuring expectations and psychological factors. Front Psychol, 8, 308. doi:10.3389/fpsyg.2017.00308 [doi]. Retrieved from PM:28321201
Drossman, D. A., & Tack, J. (2022). Rome foundation clinical diagnostic criteria for disorders of gut-brain interaction. Gastroenterology, 162(3), 675-679. doi:S0016-5085(21)03794-X [pii];10.1053/j.gastro.2021.11.019 [doi]. Retrieved from PM:34808139
Enck, P., & Klosterhalfen, S. (2021). The placebo and nocebo responses in clinical trials in inflammatory bowel diseases. Front Pharmacol., 12, 641436. doi:10.3389/fphar.2021.641436 [doi];641436 [pii]. Retrieved from PM:33867990
Flik, C. E., Bakker, L., Laan, W., van Rood, Y. R., Smout, A. J., & de Wit, N. J. (2017). Systematic review: The placebo effect of psychological interventions in the treatment of irritable bowel syndrome. World.J Gastroenterol, 23(12), 2223-2233. doi:10.3748/wjg.v23.i12.2223 [doi]. Retrieved from PM:28405151
Hauser, W., Janke, K. H., Klump, B., & Hinz, A. (2011). Anxiety and depression in patients with inflammatory bowel disease: Comparisons with chronic liver disease patients and the general population. Inflamm.Bowel.Dis, 17(2), 621-632. doi:10.1002/ibd.21346 [doi]. Retrieved from PM:20848528
Hu, Z., Li, M., Yao, L., Wang, Y., Wang, E., Yuan, J. et al. (2021). The level and prevalence of depression and anxiety among patients with different subtypes of irritable bowel syndrome: A network meta-analysis. BMC Gastroenterol, 21(1), 23. doi:10.1186/s12876-020-01593-5 [doi];10.1186/s12876-020-01593-5 [pii]. Retrieved from PM:33413140
Hulisz, D. (2004). The burden of illness of irritable bowel syndrome: Current challenges and hope for the future. J Manag.Care Pharm, 10(4), 299-309. doi:2004(10)4: 299-309 [pii];10.18553/jmcp.2004.10.4.299 [doi]. Retrieved from PM:15298528
Ishiguchi, T., Itoh, H., & Ichinose, M. (2003). Gastrointestinal motility and the brain-gut axis. Dig Endosc, 15 (2), 81-86.
Jahangiri, P., Jazi, M. S., Keshteli, A. H., Sadeghpour, S., Amini, E., & Adibi, P. (2012). Irritable Bowel Syndrome in Iran: SEPAHAN Systematic Review No. 1. Int J Prev Med, 3(Suppl 1), S1-S9. Retrieved from PM:22826748
Johansen, O., Brox, J., & Flaten, M. A. (2003). Placebo and Nocebo responses, cortisol, and circulating beta-endorphin. Psychosom.Med, 65(5), 786-790. doi:10.1097/01.psy.0000082626.56217.cf [doi]. Retrieved from PM:14508021
Kelley, J. M., Lembo, A. J., Ablon, J. S., Villanueva, J. J., Conboy, L. A., Levy, R. et al. (2009). Patient and practitioner influences on the placebo effect in irritable bowel syndrome. Psychosom.Med, 71(7), 789-797. doi:PSY.0b013e3181acee12 [pii];10.1097/PSY.0b013e3181acee12 [doi]. Retrieved from PM:19661195
Kessner, S., Sprenger, C., Wrobel, N., Wiech, K., & Bingel, U. (2013). Effect of oxytocin on placebo analgesia: a randomized study. JAMA., 310(16), 1733-1735. doi:1758733 [pii];10.1001/jama.2013.277446 [doi]. Retrieved from PM:24150470
Klosterhalfen, S., Kellermann, S., Braun, S., Kowalski, A., Schrauth, M., Zipfel, S. et al. (2009). Gender and the nocebo response following conditioning and expectancy.
J Psychosom.Res, 66(4), 323-328. doi:S0022-3999(08)00471-6 [pii];10.1016/j.jpsychores.2008.09.019 [doi]. Retrieved from PM:19302890
Kong, J., Gollub, R. L., Polich, G., Kirsch, I., Laviolette, P., Vangel, M. et al. (2008). A functional magnetic resonance imaging study on the neural mechanisms of hyperalgesic nocebo effect. J Neurosci, 28(49), 13354-13362. doi:28/49/13354 [pii];10.1523/JNEUROSCI.2944-08.2008 [doi]. Retrieved from PM:19052227
Lembo, A. J. (2020). Understanding the placebo and nocebo effects in patients with irritable bowel syndrome. Gastroenterol Hepatol.(N.Y.), 16(7), 374-376. Retrieved from PM:34035744
Liccardi, G., Senna, G., Russo, M., Bonadonna, P., Crivellaro, M., Dama, A. et al. (2004). Evaluation of the nocebo effect during oral challenge in patients with adverse drug reactions. J Investig.Allergol.Clin Immunol., 14(2), 104-107. Retrieved from PM:15301298
Longstreth, G. F., Thompson, W. G., Chey, W. D., Houghton, L. A., Mearin, F., & Spiller, R. C. (2006). Functional bowel disorders. Gastroenterology, 130(5), 1480-1491. doi:S0016-5085(06)00512-9 [pii];10.1053/j.gastro.2005.11.061 [doi]. Retrieved from PM:16678561
McLemore, B. H., McLemore, S. G., Rogers, R. R., Pederson, J. A., Williams, T. D., Marshall, M. R. et al. (2020). Nocebo effects on perceived muscle soreness and exercise performance following unaccustomed resistance exercise: A pilot study. J Funct.Morphol.Kinesiol., 5(2). doi:jfmk5020040 [pii];10.3390/jfmk5020040 [doi]. Retrieved from PM:33467255
Miller, V., Jones, H., & Whorwell, P. J. (2007). Hypnotherapy for non-cardiac chest pain: long-term follow-up. Gut., 56(11), 1643. doi:56/11/1643 [pii];10.1136/gut.2007.132621 [doi]. Retrieved from PM:17938446
Mohammed, A. A., Moustafa, H. A., Nour-Eldein, H., & Saudi, R. A. (2021). Association of anxiety-depressive disorders with irritable bowel syndrome among patients attending a rural family practice center: A comparative cross-sectional study. Gen.Psychiatr., 34(6), e100553. doi:10.1136/gpsych-2021-100553 [doi];gpsych-2021-100553 [pii]. Retrieved from PM:34970639
Montero, A. M., & Jones, S. (2020). Roles and impact of psychologists in interdisciplinary gastroenterology care. Clin Gastroenterol Hepatol., 18(2), 290-293. doi:S1542-3565(19)30857-2 [pii];10.1016/j.cgh.2019.07.067 [doi]. Retrieved from PM:31401360
Muscatello, M. R., Bruno, A., Mento, C., Pandolfo, G., & Zoccali, R. A. (2016). Personality traits and emotional patterns in irritable bowel syndrome. World.J Gastroenterol, 22(28), 6402-6415. doi:10.3748/wjg.v22.i28.6402 [doi]. Retrieved from PM:27605876
Nestoriuc, Y., Pan, Y., Kinitz, T., Weik, E., & Shedden-Mora, M. C. (2021). Informing about the nocebo effect affects patients' need for information about antidepressants-an experimental online study. Front Psychiatry, 12, 587122. doi:10.3389/fpsyt.2021.587122 [doi]. Retrieved from PM:33986697
Palsson, O. S., & Whitehead, W. E. (2013). Psychological treatments in functional gastrointestinal disorders: a primer for the gastroenterologist. Clin Gastroenterol Hepatol., 11(3), 208-216. doi:S1542-3565(12)01286-4 [pii];10.1016/j.cgh.2012.10.031 [doi]. Retrieved from PM:23103907
Palsson, O. S., Whitehead, W., Tornblom, H., Sperber, A. D., & Simren, M. (2020). Prevalence of Rome IV Functional Bowel Disorders among adults in the United States, Canada, and the United Kingdom. Gastroenterology, 158(5), 1262-1273. doi:S0016-5085(20)30001-9 [pii];10.1053/j.gastro.2019.12.021 [doi]. Retrieved from PM:31917991
Person, H., & Keefer, L. (2021). Psychological comorbidity in gastrointestinal diseases: Update on the brain-gut-microbiome axis. Prog.Neuropsychopharmacol.Biol Psychiatry, 107, 110209. doi:S0278-5846(20)30525-X [pii];10.1016/j.pnpbp.2020.110209 [doi]. Retrieved from PM:33326819
Petrie, K. J., & Rief, W. (2019). Psychobiological mechanisms of placebo and nocebo effects: Pathways to improve treatments and reduce side effects. Annu.Rev.Psychol, 70, 599-625. doi:10.1146/annurev-psych-010418-102907 [doi]. Retrieved from PM:30110575
Pigrau, M., Rodino-Janeiro, B. K., Casado-Bedmar, M., Lobo, B., Vicario, M., Santos, J. et al. (2016). The joint power of sex and stress to modulate brain-gut-microbiota axis and intestinal barrier homeostasis: implications for irritable bowel syndrome. Neurogastroenterol.Motil., 28(4), 463-486. doi:10.1111/nmo.12717 [doi]. Retrieved from PM:26556786
Planes, S., Villier, C., & Mallaret, M. (2016). The nocebo effect of drugs. Pharmacol.Res Perspect., 4(2), e00208. doi:10.1002/prp2.208 [doi];PRP2208 [pii]. Retrieved from PM:27069627
Quilty, L. C., Sellbom, M., Tackett, J. L., & Bagby, R. M. (2009). Personality trait predictors of bipolar disorder symptoms. Psychiatry Res, 169(2), 159-163. doi:S0165-1781(08)00224-2 [pii];10.1016/j.psychres.2008.07.004 [doi]. Retrieved from PM:19699536
Roderigo, T., Benson, S., Schols, M., Hetkamp, M., Schedlowski, M., Enck, P. et al. (2017). Effects of acute psychological stress on placebo and nocebo responses in a clinically relevant model of visceroception. Pain., 158(8), 1489-1498. doi:10.1097/j.pain.0000000000000940 [doi];00006396-201708000-00013 [pii]. Retrieved from PM:28471874
Schedlowski, M., Enck, P., Rief, W., & Bingel, U. (2015). Neuro-Bio-Behavioral Mechanisms of Placebo and Nocebo Responses: Implications for Clinical Trials and Clinical Practice. Pharmacol.Rev., 67(3), 697-730. doi:67/3/697 [pii];10.1124/pr.114.009423 [doi]. Retrieved from PM:26126649
Scott, D. J., Stohler, C. S., Egnatuk, C. M., Wang, H., Koeppe, R. A., & Zubieta, J. K. (2008). Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses. Arch Gen.Psychiatry, 65(2), 220-231. doi:65/2/220 [pii];10.1001/archgenpsychiatry.2007.34 [doi]. Retrieved from PM:18250260
Shiha, M. G., Asghar, Z., Thoufeeq, M., Kurien, M., Ball, A. J., Rej, A. et al. (2021). Increased psychological distress and somatization in patients with irritable bowel syndrome compared with functional diarrhea or functional constipation, based on Rome IV criteria. Neurogastroenterol.Motil., 33(10), e14121. doi:10.1111/nmo.14121 [doi]. Retrieved from PM:33719130
Spiller, R., Aziz, Q., Creed, F., Emmanuel, A., Houghton, L., Hungin, P. et al. (2007). Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut., 56(12), 1770-1798. doi:gut.2007.119446 [pii];10.1136/gut.2007.119446 [doi]. Retrieved from PM:17488783
Staats, P. S., Staats, A., & Hekmat, H. (2001). The additive impact of anxiety and a placebo on pain. Pain.Med, 2(4), 267-279. doi:10.1046/j.1526-4637.2001.01046.x [doi];PME01046 [pii]. Retrieved from PM:15102231
Stocks, N. P., Gonzalez-Chica, D., & Hay, P. (2019). Impact of gastrointestinal conditions, restrictive diets and mental health on health-related quality of life: cross-sectional population-based study in Australia. BMJ Open., 9(6), e026035. doi:bmjopen-2018-026035 [pii];10.1136/bmjopen-2018-026035 [doi]. Retrieved from PM:31253614
Strohle, A. (2000). Increased response to a putative panicogenic nocebo administration in female patients with panic disorder. J Psychiatr.Res, 34(6), 439-442. doi:S002239560000039X [pii];10.1016/s0022-3956(00)00039-x [doi]. Retrieved from PM:11165311
Symon, A., Williams, B., Adelasoye, Q. A., & Cheyne, H. (2015). Nocebo and the potential harm of 'high risk' labelling: a scoping review. J Adv Nurs, 71(7), 1518-1529. doi:10.1111/jan.12637 [doi]. Retrieved from PM:25702534
Umrani, S., Jamshed, W., & Rizwan, A. (2021). Association between psychological disorders and irritable bowel syndrome. Cureus., 13(4), e14513. doi:10.7759/cureus.14513 [doi]. Retrieved from PM:34007764
van Laarhoven, A. I. M., Vogelaar, M. L., Wilder-Smith, O. H., van Riel, P. L. C. M., van de Kerkhof, P. C. M., Kraaimaat, F. W. et al. (2011). Induction of nocebo and placebo effects on itch and pain by verbal suggestions. Pain., 152(7), 1486-1494. doi:00006396-201107000-00011 [pii];10.1016/j.pain.2011.01.043 [doi]. Retrieved from PM:21353388
Weimer, K., Enck, P., Dodd, S., & Colloca, L. (2020). Editorial: Placebo and nocebo effects in psychiatry and beyond. Front Psychiatry, 11, 801. doi:10.3389/fpsyt.2020.00801 [doi]. Retrieved from PM:32848956
Woods, M. D., Kirk, D., Agarwal, S., Annandale, E., Arthur, T., Harvey, J. et al. (2005). Vulnerable groups and access to health care: A critical interpretive review: Report for the National Co-ordinating Centre for NHS Service Delivery and Organisation R & D (NCCSDO) NCCSDO.
Yan, R., Andrew, L., Marlow, E., Kunaratnam, K., Devine, A., Dunican, I. C. et al. (2021). Dietary fibre intervention for gut microbiota, sleep, and mental health in adults with irritable bowel syndrome: A scoping review. Nutrients., 13(7). doi:nu13072159 [pii];10.3390/nu13072159 [doi]. Retrieved from PM:34201752
Zhang, T., Ma, X., Tian, W., Zhang, J., Wei, Y., Zhang, B. et al. (2022). Global research trends in irritable bowel syndrome: A bibliometric and visualized study. Front Med (Lausanne.), 9, 922063. doi:10.3389/fmed.2022.922063 [doi]. Retrieved from PM:35833106
Copyright (c) 2022 International Journal of Body, Mind and Culture
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
